Try a new search

Format these results:

Searched for:

person:katza04

in-biosketch:yes

Total Results:

10


MAGRIT phase III trial: MAGE-A3 antigen-specific cancer immunotherapy (ASCI) as adjuvant therapy in patients with completely resected stage IB-IIIA NSCLC. [Meeting Abstract]

Therasse, P.; Vansteenkiste, J. F.; Zielinski, M.; De Pas, T. M.; Atanackovic, D.; Sequist, L. V.; Vallieres, E.; Swisher, S.; Adams, S.; Passlick, B.; Eberhardt, W. E. E.; Grunenwald, D.; Mok, T.; Boyer, M.; Katz, A.; Douillard, J.; Debois, M.; Brichard, V. G.; Altorki, N. K.
ISI:000208880304635
ISSN: 0732-183x
CID: 3158512

Design and synthesis of selective PTPase 1B inhibitors targeted to the treatment of type II diabetes. [Meeting Abstract]

Primeau, J; Antane, M; Adebayo, F; Butera, J; Caufield, C; Dietrich, A; Dollings, P; Graceffa, R; Greenfield, A; Gunawan, I; Gundersen, E; Havran, L; Lennox, J; Li, ZN; Malamas, M; Mayer, S; McDevitt, B; Morris, K; Morrison, E; Pan, S; Wrobel, J; Steiner, K; Moxham, G; Sredy, J; Sawicki, D; Seestaller-Wehr, L; Demick, ME; Taylor, J; Baeder, W; Xu, WX; Parris, K; Katz, A
ISI:000087246200028
ISSN: 0065-7727
CID: 1409362

Tunable lamp-based tissue fluorescent spectroscopy (TFS) of Barrett's esophagus and esophageal carcinoma: An ex-vivo study [Meeting Abstract]

Basuk, PM; Chu, M; Katz, A; Savage, H; Godwin, TN; Altorki, NK; Grendell, JH; Alfano, RR
ISI:000079778400198
ISSN: 0016-5085
CID: 3412692

Native fluorescence spectroscopy of normal and malignant epithelial cells

Ganesan, S; Sacks, P G; Yang, Y; Katz, A; Al-Rawi, M; Savage, H E; Schantz, S P; Alfano, R R
Native fluorescence spectroscopy of normal human oral and malignant epithelial cells was studied under uv excitation. Differences were observed in the excitation spectra between normal and malignant epithelial cells for 340 nm emission. The observed differences may be utilized for both discrimination and changes associated with the amino acid residues in the cellular proteins.
PMID: 9925283
ISSN: 0305-7232
CID: 276392

Unmasking by soluble IL-6 receptor of IL-6 effect on metastatic melanoma: growth inhibition and differentiation of B16-F10.9 tumor cells

Oh, J W; Katz, A; Harroch, S; Eisenbach, L; Revel, M; Chebath, J
Interleukin-6 (IL-6) inhibits the growth of melanocytes and of early stage melanoma cells, but not that of advanced melanoma cells. The in vitro IL-6 response can be restored in the highly metastatic melanoma B16-F10.9 by addition of recombinant soluble IL-6 receptor alpha-chain (sIL-6R). The F10.9 cells then undergo irreversible growth-arrest and show increased adherence with changes from epithelioid to spindleoid morphology. The sIL-6R is required for IL-6 to induce a sustained activation of the various Stat transcription factors which bind to specific IL-6 inducible enhancers. The sIL-6R and IL-6 combination causes an increase in the level of the anti-oncogenic transcription factor IRF-1 protein and DNA-binding, which remain elevated for 24 h. The promoter activity of the anti-oncogenic p21/Waf-1/Cip-1 gene is induced and accumulation of the p21 protein is observed. These results illustrate the potent agonist activity of sIL-6R on molecular pathways which could mediate the growth-arrest and differentiation of the metastatic melanoma cells. Previously observed antimetastatic effects of IL-6 therapy in mice bearing F10.9 tumors may be at least partly due to direct growth inhibition and differentiation elicited by sIL-6R present in biological fluids.
PMID: 9247310
ISSN: 0950-9232
CID: 1434852

Multi-focal ERGs and visual fields in diabetic patients with macular edema [Meeting Abstract]

Greenstein, VC; Holopigian, K; Seiple, W; Kahanowicz, R; Katz, A
ISI:A1997WN21500373
ISSN: 0146-0404
CID: 53242

Innate cellular fluorescence reflects alterations in cellular proliferation

Zhang, J C; Savage, H E; Sacks, P G; Delohery, T; Alfano, R R; Katz, A; Schantz, S P
BACKGROUND AND OBJECTIVE: The objective of this study was to examine the question of whether unique spectral patterns were associated with cell proliferation and could be identified by comparing the fluorescence pattern of slow to rapid growing cells. STUDY DESIGN/MATERIALS AND METHODS: Three in vitro model systems, (A431 cells inhibited by EGF, serum-starved 3T3 fibroblasts, and normal oral epithelial cells exposed to TGF beta), were analyzed using fluorescence spectroscopy. Growth status was monitored by cell number, 3H-thymidine incorporation, and flow cytometry. RESULTS: The excitation spectra (lambda ex 240-430 nm, lambda em 450 nm) effectively distinguished slow and rapid growing cells in all three systems. Statistical analysis of the ratios of the main broad peak (320-350 nm) to a point on the down-slope of the curve at 370 nm was statistically significant. Ratios in the emission scan (lambda ex 340 nm, lambda em 360-660 nm) could separate slow and rapid growing A431 and oral epithelial cells (P = 0.0001 and P = 0.023, respectively), but not slow and fast growing 3T3 cells (P = 0.56). CONCLUSION: Innate cellular fluorescence has the potential to discriminate proliferating and nonproliferating cell populations.
PMID: 9138261
ISSN: 0196-8092
CID: 276482

Successful treatment of progressive outer retinal necrosis syndrome [Case Report]

Spaide, R F; Martin, D F; Teich, S A; Katz, A; Toth, I
PURPOSE: Progressive outer retinal necrosis is a destructive retinopathy found in patients with acquired immune deficiency syndrome. Treatment of this disorder has been unsuccessful in reported patient series, with the patients experiencing profound bilateral loss of vision. METHODS: We treated six patients with combination antiviral therapy, usually with intravenous foscarnet and either ganciclovir or acyclovir. RESULTS: These six patients retained a visual acuity of 20/100 or better in at least one eye for the remainder of their lives (a period > 4 months for each patient). Retinal detachments developed in four patients, for which vitrectomy and silicone oil tamponade were required. CONCLUSIONS: A combination of intravenous antiviral therapy and aggressive vitrectomy techniques to repair any associated detachments may allow the preservation of useful visual acuity in patients with progressive outer retinal necrosis. This is the first reported series of successful long-term treatment of patients with this disorder
PMID: 9002130
ISSN: 0275-004x
CID: 103606

An interlocking auricular composite graft

Ratner, D; Katz, A; Grande, D J
BACKGROUND:Full-thickness defects of the nasal alar rim are relatively common following Mohs micrographic surgery for the treatment of long-standing or recurrent skin tumors. Composite grafts provide an excellent cosmetic and functional alternative for the repair of such defects. OBJECTIVE:A useful technique of auricular composite graft placement for reconstruction of full-thickness nasal alar rim defects is described. METHODS:The cartilaginous portion of the graft is extended beyond the borders of the soft tissue defect so that two cartilaginous pegs frame the lateral aspects of the graft. These pegs are then inserted into pockets prepared within the alar tissue of both sides of the defect, such that the graft interlocks with its recipient bed. A series of diagrams as well as a set of photographs from a representative case are provided, along with accompanying commentary, so as to enable the surgeon to incorporate this technique easily into his/her practice. CONCLUSION/CONCLUSIONS:The interlocking auricular composite graft technique permits increased graft stability, with decreased shearing forces of the graft over its recipient bed, and a larger surface area for revascularization, resulting in an increased probability of graft survival. This technique provides an elegant single stage alternative to current reconstructive techniques for full-thickness nasal alar rim defects measuring less than 1.5 cm in diameter.
PMID: 7655799
ISSN: 1076-0512
CID: 3183512

Interleukin-6: effects on tumor models in mice and on the cellular regulation of transcription factor IRF-1

Revel, M; Katz, A; Eisenbach, L; Feldman, M; Haran-Ghera, N; Harroch, S; Chebath, J
PMID: 7545371
ISSN: 0077-8923
CID: 1434752